EUVIMEDOdkrijte EUVIMED
Systematische ÜbersichtMetaanalyseOpen access · CC BY-NC-ND 4.0

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

Andrea Lancz iD, Fanni Adél Meznerics iD, Renáta Árok iD, Anna Sára Lengyel, Bence Szabó iD, Péter Hegyi iD, Norbert Kiss iD, András Bánvölgyi iD

International Journal of Dermatology · 2026-04 · 65 (4) · 724-736

DOI: 10.1111/ijd.70246 ↗

At a glance

Systematische Übersicht in International Journal of Dermatology, published online on 2026-01-06. Written by Andrea Lancz and 7 co-authors. Institution: Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary. Major MEDLINE topics: Prurigo, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Cited 7 times so far (Crossref); 171 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative. A systematic search of PubMed, Embase, and CENTRAL databases was conducted on November 20, 2023, to identify studies assessing treatments for PN. Primary outcomes were changes in pruritus and quality of life. Safety was evaluated by adverse event incidence. Random‐effects meta‐analyses were conducted when sufficient data were available. Of 4914 records screened, 128 studies met the inclusion criteria, of which 25 were included in the meta‐analysis. In studies of dupilumab, treatment was associated with marked reductions in pruritus (mean difference [MD], −5.76; 95% confidence interval [CI], −6.86 to −4.67) and significant improvement in quality of life (MD, −11.84; 95% CI, −22.76 to −0.92), with adverse events reported in 13% of patients (95% CI, 0.02–0.52). Phototherapy achieved complete responses in 23% (95% CI, 9%–48%), partial responses in 60% (95% CI, 39%–78%), and no response in 7% (95% CI, 1%–40%). Thalidomide was associated with complete, partial, and no response rates of 15% (95% CI, 1%–71%), 49% (95% CI, 23%–75%), and 12% (95% CI, 6%–23%), respectively. Dupilumab offers consistent, clinically meaningful improvements in PN with a favorable safety profile, supporting its use as the preferred first‐line treatment. Phototherapy and thalidomide remain alternatives for selected patients but achieve complete clearance in few cases and carry greater safety concerns.

Subjects

MeSH terms (MEDLINE)

PrurigoAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansQuality of LifeTreatment OutcomePhototherapyPruritus

Author keywords

dupilumabphototherapyprurigo nodularisthalidomide

Substances

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Authors and institutions

  • Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Markusovszky University Teaching Hospital, Department of Internal Medicine, Szombathely, Hungary.
  • Bajcsy-Zsilinszky Hospital and Clinic, Department of Pharmacy, Budapest, Hungary.
  • HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.

ORCID profiles: Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi

Cite

APA

Lancz, A., Meznerics, F. A., Árok, R., Lengyel, A. S., Szabó, B., Hegyi, P., Kiss, N., & Bánvölgyi, A. (2026). Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis. International Journal of Dermatology, 65(4), 724-736. https://doi.org/10.1111/ijd.70246

Vancouver

Lancz A, Meznerics FA, Árok R, Lengyel AS, Szabó B, Hegyi P, et al. Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis. International Journal of Dermatology. 2026;65(4):724-736. doi:10.1111/ijd.70246

BibTeX
@article{Lancz2026,
  author = {Lancz, Andrea and Meznerics, Fanni Adél and Árok, Renáta and Lengyel, Anna Sára and Szabó, Bence and Hegyi, Péter and Kiss, Norbert and Bánvölgyi, András},
  title = {Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {4},
  pages = {724--736},
  doi = {10.1111/ijd.70246}
}
Start for free →